m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02794)
Name
PF-543
Synonyms
sphingosine kinase 1 Inhibitor II; PF 543
    Click to Show/Hide
Status
Investigative
Structure
Formula
C27H31NO4S
InChI
1S/C27H31NO4S/c1-21-14-24(20-33(30,31)27-7-3-2-4-8-27)16-26(15-21)32-19-23-11-9-22(10-12-23)17-28-13-5-6-25(28)18-29/h2-4,7-12,14-16,25,29H,5-6,13,17-20H2,1H3/t25-/m1/s1
InChIKey
NPUXORBZRBIOMQ-RUZDIDTESA-N
PubChem CID
66577038
TTD Drug ID
D08SND
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Sphingosine kinase 1 (SPHK1)
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Sphingosine kinase 1 (SPHK1) is a therapeutic target for PF-543. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PF-543 through regulating the expression of Sphingosine kinase 1 (SPHK1). [1], [2]
References
Ref 1 ALKBH5 Regulates SPHK1-Dependent Endothelial Cell Angiogenesis Following Ischemic Stress. Front Cardiovasc Med. 2022 Jan 20;8:817304. doi: 10.3389/fcvm.2021.817304. eCollection 2021.
Ref 2 Characterization of B-5354c, a new sphingosine kinase inhibitor, produced by a marine bacterium. J Antibiot (Tokyo). 2000 Aug;53(8):759-64. doi: 10.7164/antibiotics.53.759.